Nanotechnology Now

Heifer International

Wikipedia Affiliate Button


Home > Press > Genovis AB Financial Report

Interim Report January-September 2010

Genovis AB Financial Report

Sweden | Posted on November 5th, 2010


• Net sales climbed to SEK 407k (238k)
• Loss after financial items dropped to SEK 2,874k (loss: 3,050k)
• Net loss for the period fell to SEK 2,863k (loss: 3,050k)
• Earnings per share increased to SEK -0.07 (-0.22)


• Net sales climbed to SEK 965k (508k)
• Loss after financial items dropped to SEK 8,023k (loss: 9,390k)
• Net loss for the period fell to SEK 7,991k (loss: 9,390k)
• Earnings per share increased to SEK -0.19 (-0.67)

Comments from the CEO

During the quarter we continued to work toward two of our short-term goals: to increase sales of products from the protein engineering portfolio and to intensify product development of multimodal nanoparticles. We've seen a clear increase in both the number of customers and sales during the year and we want to further accelerate the pace. To achieve this objective, during the third quarter we strengthened our sales organization and we chose to focus on new and existing customers among biotech and pharmaceutical companies. This category of customers primarily works with characterization of antibody molecules. They have relatively recently begun testing our enzymes from the protein engineering portfolio and they use them primarily for analysis at the discovery level. To increase volumes within this target group we are working with customer meetings and marketing with the aim of ensuring that our enzymes and methods will become the obvious choice. This standard will not only apply for early research projects, but continue as quality control during clinical trials, and later even in production of antibody-based drugs. One way to achieve this objective is to work on product development in close consultation with our customers. Such feedback has resulted in a new product, FragIT, which we are launching in November.

In September we presented the first results from the Sentinel node project at the World Molecular Imaging Congress (WMIC) in Kyoto, Japan. The need for new imaging technologies at the preclinical level is growing and it is encouraging to see that multimodal nanoparticles have the potential to contribute improved performance, higher resolution, and more reliable analysis. Genovis' product development of nanoparticles for multimodal imaging is progressing according to plan and is now in a phase when we are focusing on optimization of modalities, image interpretation, and targeting using antibody molecules. We have also expanded our partnership with Lund Bioimaging Center, our partner that we've been working with on the Sentinel node research project.

Overview of Operations

Genovis develops and sells innovative technologies that will facilitate our customers' preclinical* research. The products we have launched to date consist of nanostructures and enzymes (proteins). We conduct research and development projects that focus on design, production, and characterization of nanostructures. The nanostructures and methods that Genovis focuses on can be used as contrast in medical imaging and as carriers of various substances in the development of new drug delivery methods. Our customers are primarily within the life sciences industry and academic research. The Genovis operation largely consists of research and development of new technology, though we have initiated some sales over the past two years.

* "Preclinical studies" refers to pharmaceutical research carried out before a product is sufficiently documented to be studied in humans.


About Genovis
Genovis is a biotech company on the leading edge of nanotechnology and nanoparticles. The company’s patented nano-induced magnetic transfer (NIMT®) technology was developed to facilitate effective preclinical research for the life science industry. Genovis shares are listed on Nasdaq OMX First North and Thenberg & Kinde Fondkommission is our certified adviser.

For more information, please click here

Sarah Fredriksson
CEO, Genovis AB
Tel: +46 46 10 12 35

Copyright © Genovis

If you have a comment, please Contact us.

Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.

Delicious Digg Newsvine Google Yahoo Reddit Magnoliacom Furl Facebook

Related News Press

News and information

Discovery of nanotubes offers new clues about cell-to-cell communication July 2nd, 2015

Nanospiked bacteria are the brightest hard X-ray emitters July 2nd, 2015

Engineering the world’s smallest nanocrystal July 2nd, 2015

Producing spin-entangled electrons July 2nd, 2015


Iranian Scientists Find Simple, Economic Method to Synthesize Antibacterial Nanoparticles July 2nd, 2015

Leti Announces Launch of First European Nanomedicine Characterisation Laboratory: Project Combines Expertise of 9 Partners in 8 Countries to Foster Nanomedicine Innovation and Facilitate Regulatory Approval July 1st, 2015

Carnegie Mellon chemists characterize 3-D macroporous hydrogels: Methods will allow researchers to develop new 'smart' materials June 30th, 2015

Chitosan coated, chemotherapy packed nanoparticles may target cancer stem cells June 30th, 2015


Nanospiked bacteria are the brightest hard X-ray emitters July 2nd, 2015

Engineering the world’s smallest nanocrystal July 2nd, 2015

Producing spin-entangled electrons July 2nd, 2015

NIST Group Maps Distribution of Carbon Nanotubes in Composite Materials July 2nd, 2015

Financial Reports

Aspen Aerogels to Webcast 2015 Annual Meeting of Stockholders June 11th, 2015

Industrial Nanotech, Inc. Provides Update June 8th, 2015

PEN Inc. Announces First Quarter Financial Results: Investor Webcast and Business Update Set for May 21, 1 pm EDT May 13th, 2015

Arrowhead to Report Fiscal 2015 Second Quarter Financial Results May 4th, 2015


Engineering the world’s smallest nanocrystal July 2nd, 2015

Nanometric sensor designed to detect herbicides can help diagnose multiple sclerosis June 23rd, 2015

Newly-Developed Biosensor in Iran Detects Cocaine Addiction June 23rd, 2015

Researchers first to show that Saharan silver ants can control electromagnetic waves over an extremely broad range of the electromagnetic spectrum—findings may lead to biologically inspired coatings for passive radiative cooling of objects June 19th, 2015


Oxford Instruments’ TritonXL Cryofree dilution refrigerator selected for the Oxford NQIT Quantum Technology Hub project June 30th, 2015

Centre for Process Innovation pilots Beneq’s breakthrough roll-to-roll ALD system for moisture barrier films June 3rd, 2015

Argonne chooses Beneq’s TFS 500 Atomic Layer Deposition System: Modularity and flexibility make for a natural choice May 14th, 2015

New JEOL E-Beam Lithography System to Enhance Quantum NanoFab Capabilities May 6th, 2015

The latest news from around the world, FREE

  Premium Products
Only the news you want to read!
 Learn More
University Technology Transfer & Patents
 Learn More
Full-service, expert consulting
 Learn More

Nanotechnology Now Featured Books


The Hunger Project